Paul Peter Tak, M.D., Ph.D., FMedSci
2022
In 2022, Paul Peter Tak, M.D., Ph.D., FMedSci earned a total compensation of $1.8M as Chief Executive Officer at Candel Therapeutics, a 93% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $259,625 |
|---|---|
| Option Awards | $351,043 |
| Salary | $670,000 |
| Stock Awards | $334,999 |
| Other | $229,304 |
| Total | $1,844,971 |
FMedSci received $670K in salary, accounting for 36% of the total pay in 2022.
FMedSci also received $259.6K in non-equity incentive plan, $351K in option awards, $335K in stock awards and $229.3K in other compensation.
Rankings
In 2022, Paul Peter Tak, M.D., Ph.D., FMedSci's compensation ranked 1,883rd out of 5,672 executives tracked by ExecPay. In other words, FMedSci earned more than 66.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,883 out of 5,672 | 67th |
Division Manufacturing | 992 out of 3,081 | 68th |
Major group Chemicals And Allied Products | 412 out of 1,396 | 71st |
Industry group Drugs | 377 out of 1,297 | 71st |
Industry Biological Products, Except Diagnostic Substances | 96 out of 295 | 68th |
Source: SEC filing on May 23, 2023.
FMedSci's colleagues
We found two more compensation records of executives who worked with Paul Peter Tak, M.D., Ph.D., FMedSci at Candel Therapeutics in 2022.